P21-activated kinase 1 is a potential biomarker of human prostate cancer

7^th International Conference and Expo on Molecular & Cancer Biomarkers

September 15-16, 2016 Berlin, Germany

Gang Chen

Jinshan Hospital- Fudan University, China

Posters & Accepted Abstracts: J Mol Biomark Diagn

Abstract :

Prostate cancer (PCa) is the most common malignant tumor without clinical symptoms at an early stage in men. However, its etiology and pathogenesis remain unclear. P21-activated kinase 1 (PAK1) is a member of a family of serine/threonine kinases highly conserved throughout evolution. It has been shown that PAK1 is involved in cancer cell growth, invasion and metastasis, but little is known about PAK1 expression in patients with PCa. In this study, a total of 113 patients with PCa and benign prostate hyperplasia (BPH) who were treated in our hospital were analyzed retrospectively. The expression of PAK1 in prostate cancer and benign prostate hyperplasia tissues was determined by immunohistochemistry and Western blot. PAK1 protein expression was significantly increased in patients with PCa compared to patients with BPH (PCa vs. BPH, P<0.05). PAK1 expression was associated with PSA, AKP and BIM. The expression of PAK1 at the mRNA and protein levels in PCa cell lines, such as DU145, PC-3, LNCaP and RWPE-1, was determined by quantitative real-time PCR and Western blot, respectively. The level of PAK1 expression was higher in DU145 cells than those in PC-3, LNCaP and RWPE-1 cells. Furthermore, PAK1 expression was regulated by mTOR inhibitor Rapamycin and mTOR activator MHY1485 in DU145, LNCaP and RWPE-1 cells. These data indicate the involvement of the mTOR-mediated pathway in the regulation of PAK1. In conclusion, this study demonstrated that PAK1 is upregulated in human PCa and mediated by the mTOR signaling pathway. PAK1 may be a PCa marker and therapeutic target.

Biography :

Email: chgan305@163.com